Comparison
While AOD-9604 is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials71111115, FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38.
While AOD-9604 works as a synthetic fragment of human growth hormone corresponding to residues 176–191 with an added N-terminal tyrosine, retaining lipolytic but not growth-promoting actions; proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue, partly via β3-adrenergic pathways without significantly activating the full GH receptor–IGF-1 axis6171111, FOXO4-DRI is a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38.
AOD-9604 is 16 amino acids long, whereas FOXO4-DRI is shorter as it has a length of amino acids. AOD-9604 is made up of a sequence of Tyrosine, Leucine, Arginine, Isoleucine, Valine, Glutamine, Cysteine, Arginine, Serine, Valine, Glutamic acid, Glycine, Serine, Cysteine, Glycine, Phenylalanine. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset.
AOD-9604
FOXO4-DRI
Intracellular target is the FOXO4–p53 protein–protein interaction interface; it does not signal via a traditional cell-surface receptor38
AOD-9604
GH1
FOXO4-DRI
FOXO4
No related articles are linked to these peptides yet.